Kratom and its alkaloids: A balanced review of the science and state regulation
Kratom (Mitragyna speciosa) is a tree native to Southeast Asia, where its leaves have been chewed or brewed into tea for generations to manage pain, combat fatigue, and ease opioid withdrawal. In recent decades, its use has spread to Europe and the United States, where it has become a subject of intense scientific, regulatory, and public health debate. In the U.S., kratom is mostly sold as loose powder or in capsules made from minimally processed leaves, though a growing market now offers concentrated extracts with stronger effects.
This paper offers a balanced, evidence-based review of the scientific literature on kratom and its primary alkaloids—mitragynine and 7-hydroxymitragynine (7-OH)—as well as its various product forms, with a focus on informing state-level policy.
National survey data show that kratom use remains relatively rare, with less than one percent of adults reporting any past-year use, though prevalence rises significantly in certain subgroups, such as those with serious psychological distress or substance use histories. The typical kratom consumer in the U.S. is middle-aged, non-Hispanic white, and male, and survey data consistently show that pain management and reducing or replacing opioids are the main reasons for use.
Kratom’s pharmacological profile is both unusual and consequential for its therapeutic promise and potential risks. Its major alkaloids act on the same receptors as opioids, but only partially activate them. This mechanism produces kratom’s pain-relieving effects while also contributing to a potential for dependence and withdrawal symptoms. Kratom is further distinguished from classic opioids by its significantly lower risk of overdose, with mitragynine posing no risk of slowed breathing, the primary cause of fatal opioid overdose. This means that products with alkaloid compositions similar to unprocessed leaves (mitragynine-dominant) pose essentially no risk of fatal respiratory depression.
The overdose evidence on 7-OH and concentrated products is more mixed. Animal studies indicate that direct, intravenous 7-OH administration can slow breathing. However, it is unclear how this translates to typical oral use in humans.
Based on all available evidence, this risk appears to be minimal compared to classic opioids and is reversible with the same widely available medication used to reverse opioid overdose. Concentrated products may be more effective for severe chronic pain or substance use disorder but may also pose a heightened risk of dependence and withdrawal.
Few consumers of kratom report serious adverse events and few report concerns about kratom use disorder. When kratom use disorder does become clinically significant, studies show it responds well to buprenorphine/naloxone treatment, the same medication used for opioid use disorder. Overdose deaths linked to all types of kratom products also remain exceedingly low, even among those using high doses of concentrated products.
The most comprehensive analysis, reviewing over 27,000 overdose deaths between 2016 and 2017, identified just 152 overdoses “involving” kratom. Just seven of those deaths involved solely kratom. The rest involved the co-use of classic opioids, like fentanyl and other substances with established overdose dangers.
For concentrated products, specifically, federal agencies have identified just 85 overdose cases since 2019, 55 of which were fatal and most of which involved substances in addition to 7-OH. Given its prevalence of use, the near absence of overdose deaths even tangentially related to these products indicates a low risk. Researchers have estimated that the risk of death among those consuming kratom is approximately 1,390 times lower when compared to those using any opioid.
The most consistently documented risks related to kratom products stem not from the plant itself but from the unregulated supply chain. Testing has repeatedly found kratom products contaminated with heavy metals, Salmonella, and residual solvents, and frequently mislabeled with inaccurate alkaloid concentrations, making safe dosing difficult for consumers.
In response to its rising popularity and concerns surrounding its use, states have begun to adopt regulations on kratom products. As of June 2026, eight states ban all kratom and 17 have adopted regulatory frameworks that may include a minimum age of purchase, rules on manufacturing and labeling, and product standards that may include limits on alkaloid concentrations.
This study finds that most of these state approaches are improperly calibrated to achieve maximum consumer safety and optimal public health outcomes.
The research reviewed in this paper associates prohibition with higher overdose mortality and adverse events as users shift to unregulated markets and products and associates enforced regulation with reduced contamination risk. Based on this evidence, the paper recommends that states adopt age restrictions, good manufacturing practice (GMP) standards, mandatory product testing, and clear labeling requirements for both leaf kratom and concentrated products, rather than banning kratom outright.
Full study — Kratom and its alkaloids: A balanced review of the science and state regulation
The post Kratom and its alkaloids: A balanced review of the science and state regulation appeared first on Reason Foundation.
Source: https://reason.org/policy-brief/kratom-and-its-alkaloids-a-balanced-review-of-the-science-and-state-regulation/
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.

